Medindia

X

Bioheart, Inc., Added to Russell Microcap Index

Thursday, July 3, 2008 General News J E 4
Advertisement
SUNRISE, Fla., July 2 Bioheart, Inc.(Nasdaq: BHRT) a biotechnology company that is focused on the development ofautologous (patient-derived) cell therapies and devices for the treatment ofchronic and acute heart damage, today announced it has been added to theRussell Microcap Index after the Russell Investment Group reconstituted itscomprehensive set of U.S. and global equity indexes on June 27, 2008.

According to the Russell Investment Group, the Russell indexes are widelyused by investment managers and institutional investors for index funds and asbenchmarks for passive and active investment strategies. The Company willhold its membership until Russell reconstitutes its indexes in June 2009.

"We are pleased with our inclusion in this index, which reflects ourcontinued momentum," said William Kline, Chief Financial Officer, Bioheart,Inc. "We are confident that our inclusion in this index will generate greaterinterest in our stock among institutional investors."

The Russell Microcap Index measures the performance of the microcapsegment of the U.S. equity market. It includes 1,000 of the smallestsecurities in the small-cap Russell 2000(R) Index based on a combination oftheir market cap and current index membership as well as the next 1,000securities below the index.

ABOUT BIOHEART, INC.

Bioheart, Inc. (NASDAQ: BHRT) is a biotechnology company focused on thediscovery, development and, subject to regulatory approval, commercializationof autologous cell therapies for the treatment of chronic and acute heartdamage. Its lead product candidate, MyoCell(R), is an innovative clinicalcell therapy designed to populate regions of scar tissue within a patient'sheart with new living cells for the purpose of improving cardiac function inchronic heart failure patients. The Company's pipeline includes multipleproduct candidates for the treatment of heart damage, including Bioheart AcuteCell Therapy, an autologous, adipose cell treatment for acute heart damage,and MyoCell(R) SDF-1, a therapy utilizing autologous cells that aregenetically modified to express additional potentially therapeutic growthproteins. For more information on Bioheart, visit http://www.bioheartinc.com.

MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.

About Russell:

Russell Investment Group aims to improve financial security for people byproviding strategic advice, world-class implementation, state-of-the-artperformance benchmarks, and a range of institutional-quality investmentproducts. With more than $200 billion in assets under management, Russellserves individual, institutional and advisor clients in more than 40countries. Russell provides access to some of the world's best money managers.It helps investors put this access to work in corporate defined benefit anddefined contribution plans, and in the life savings of individual investors.Russell's indexes are unmanaged and cannot be invested in directly. For moreinformation on Russell indexes, go to http://www.russell.com/.Contact: William Kline Lytham Partners, LLC Chief Financial Officer Joe Diaz (954) 835-1500 Joe Dorame Robert Blum (602) 889-9700

SOURCE Bioheart, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
July 28, 2008: Status of Unlawfully Expelled Ahmad...
S
Transcept Pharmaceuticals Appoints Key Senior Exec...